Sackman v. Liggett Group, Inc.

920 F. Supp. 357, 35 Fed. R. Serv. 3d 36, 1996 U.S. Dist. LEXIS 11701, 1996 WL 128107
CourtDistrict Court, E.D. New York
DecidedMarch 19, 1996
DocketCV 93-4166 (ADS)
StatusPublished
Cited by9 cases

This text of 920 F. Supp. 357 (Sackman v. Liggett Group, Inc.) is published on Counsel Stack Legal Research, covering District Court, E.D. New York primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Sackman v. Liggett Group, Inc., 920 F. Supp. 357, 35 Fed. R. Serv. 3d 36, 1996 U.S. Dist. LEXIS 11701, 1996 WL 128107 (E.D.N.Y. 1996).

Opinion

MEMORANDUM OPINION AND ORDER

BOYLE, United States Magistrate Judge.

This is a diversity action. The plaintiffs, Janet and Joseph Sackman (hereinafter called the “Sackmans”), are citizens of New York. The defendant tobacco company, The Liggett Group, Inc. (hereinafter called “Liggett”) is a Delaware corporation. The Sack-mans are suing Liggett for damages resulting from the cancer plaintiff Janet Sackman suffered, allegedly caused by her use of Liggett’s product, Chesterfield cigarettes.

Currently before this court is the determination of the applicability of several privi *360 leges asserted by Liggett with regard to documents related to scientific research projects into medical issues relating to tobacco use conducted by the Council on Tobacco Research, Special Projects. Liggett has submitted 123 documents for in camera review by the court to which it claims the attorney-client and/or work-produet privilege. The court has reviewed the documents. The parties have submitted supporting documents and briefs on the law. The court heard oral argument on January 22,1996.

I. Contentions of The Parties and Background

The documents at issue involve the Council on Tobacco Research (hereinafter called “CTR”), an entity existing pursuant to the laws of the State of New York which funded allegedly independent unbiased scientific research relating to any causal nexus between tobacco use and health. All the members of CTR are tobacco companies including the defendant, Liggett. CTR is the successor of the Tobacco Industry Research Committee (“TIRC”), formed by several tobacco compames in 1954. The purpose of its formation is embodied in a document entitled “A Frank Statement to the Public — By the Makers of Cigarettes” (“Frank Statement”). The Frank Statement was published in several national newspapers, and in part states:

We accept an interest in people’s health as a basic responsibility, paramount to every other consideration in our business. We believe the products we make are not injurious to health____ We are pledging aid and assistance to the research effort into all phases of tobacco use and health____ In charge of [the TIRC] will be a scientist of impeachable integrity and national repute. In addition there will be an Advisory Board of scientists disinterested in the cigarette industry. Frank Statement, Exhibit “B” to Letter, dated November 21, 1995 from plaintiffs counsel Kenneth B. McClain.

Although Liggett was not one of the founding members of TIRC, it became a member in 1964. During testimony before Congress in 1994, Dr. James F. Glenn, then Chairman of CTR, reconfirmed the mission, testifying that CTR “seek[s] scientific truth” on tobacco and related health issues. Regulation of Tobacco Products: Hearings Before the Subcommittee on Health and the Environment of the Committee on Energy and Commerce, 103rd Cong., 2d Sess. 103-153 at 341 (April 28, May 17 and 26,1994) (testimony of James F. Glenn, Chairman, Council for Tobacco Research, USA).

CTR funded scientific research projects through research grants and awards. Letter of James Kearney, dated November 22,1995 at 2. Liggett states that many of the research projects it supported were also provided funding by “the federal government and various national health organizations such as the National Institute of Health, the National Cancer Institute, the Environmental Protection Agency, the American Cancer Society, and the American Heart Association____” Id. Liggett asserts that all researchers were free to publish their research results, including Special Projects researchers involved here, and all such projects undertaken by CTR are reported in CTR’s annual reports which are available to the public.

There are two methods of scientific research grant funding through CTR. The first is its grant-in-aid program, under which research proposals are reviewed by CTR’s Scientific Advisory Board (also referred to as “SAB”), comprised of eminent, independent scientists in their respective fields. The SAB makes decisions on whether research requests should be funded by CTR. The second funding method was through CTR’s Special Projects, in which the tobacco companies themselves, on the advice and recommendation of counsel, decide whether or not to approve a request for funding. Liggett claims that Special Projects funded research that a member tobacco company, or companies, believed would be beneficial in future litigation or Congressional hearings. SAB did not participate in any way in the selection process. 1

*361 The Saekmans seek discovery of the 123 documents relating to Liggett’s participation in CTR Special Projects program, asserting that the documents are not privileged, and if they are, they fall within the crime-fraud exception to the privilege.

Although there is some overlapping, the documents fall into three main categories. The first category, comprising the overwhelming majority of the documents, are documents to or from counsel relating to specific scientific projects, either conducted or recommended to be conducted, under CTR Special Projects. The second category consists of documents of minutes and agenda of meetings of various general counsel to the tobacco companies in which CTR Special Projects, or a particular project, is discussed. The third category consists of documents relating to meetings held by tobacco company executives wherein CTR Special Projects were discussed. Two miscellaneous documents involve a description of various methods of tobacco product research and public relations, and annual budget expenditures by Liggett for research and other legal expenses, which include references to CTR Special Projects.

The Sackman’s fraud argument is based on the claim that CTR was held out to the public to be an independent non-profit entity dedicated to scientific research to serve the interests of public health. Letter of Kenneth B. McClain, dated November 28, 1995 at 3. The Saekmans assert that CTR'Special Projects did not fund independent research on health related smoking issues for the public good, but instead focused on research likely to produce findings — intended for public relations purposes and in the tobacco companies’ economic interest — that would disprove or undermine any causational link between health and the use of tobacco products. The Saekmans point to the counsels’ distinct role in the selection of research for Special Projeets and to the absence of participation by SAB to support their claim that Special Projects lacked scientific value, and was devoid of any concern with public health issues.

Liggett implicitly acknowledges the lack of any independence in CTR’s goals with respect to Special Projects by asserting that the projects were undertaken to assist in the defense of anticipated litigation against member tobacco companies. Liggett asserts that the scientists and/or medical physicians involved in Special Projects research were free to publish their results.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

E.I. Du Pont De Nemours & Co. v. Forma-Pack, Inc.
718 A.2d 1129 (Court of Appeals of Maryland, 1998)
Sineise v. Texaco Carribean, Inc.
38 V.I. 368 (Virgin Islands, 1998)
Glidden Co. v. Jandernoa
173 F.R.D. 459 (W.D. Michigan, 1997)
Nance v. Thompson Medical Co.
173 F.R.D. 178 (E.D. Texas, 1997)
Tartaglia v. Paul Revere Life Insurance
948 F. Supp. 325 (S.D. New York, 1996)
Burton v. R.J. Reynolds Tobacco Co.
167 F.R.D. 134 (D. Kansas, 1996)

Cite This Page — Counsel Stack

Bluebook (online)
920 F. Supp. 357, 35 Fed. R. Serv. 3d 36, 1996 U.S. Dist. LEXIS 11701, 1996 WL 128107, Counsel Stack Legal Research, https://law.counselstack.com/opinion/sackman-v-liggett-group-inc-nyed-1996.